Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948 In Chronic Lymphocytic Leukemia At The 66Th American Society Of Hematology Annual Meeting
Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948 In Chronic Lymphocytic Leukemia At The 66Th American Society Of Hematology Annual Meeting . (MENAFN - GlobeNewsWire - Nasdaq) Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108973617/Nurix-Therapeutics-Presents-New-Positive-Data-From-Phase-1A1B-Clinical-Trial-Of-NX-5948-In-Chronic-Lymphocytic-Leukemia-At-The-66Th-American-Society-Of-Hematology-Annual-Meeting
2024-12-09
rss
(MENAFN - GlobeNewsWire - Nasdaq) Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least ...
Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948 In Chronic Lymphocytic Leukemia At The 66Th American Society Of Hematology Annual Meeting